User:Mr. Ibrahem/Belinostat

Belinostat, sold under the brand name Beleodaq, is a medication used to treat peripheral T-cell lymphoma (PTCL). It is used when other treatments have failed. Regarding if it improves life expectancy is unclear as of 2020. It is given by injection into a vein.

Common side effects include nausea, tiredness, fever, and low red blood cells. Other side effects may include low platelets, low white blood cells, infection, liver problems, and tumor lysis syndrome. Use in pregnancy may harm the baby. It is a histone deacetylase inhibitor.

Belinostat was approved for medical use in the United States in 2014. It was given an orphan designation in Europe in 2012. In the United States a vial of 500 mg costs about 2,100 USD as of 2022.